文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA-617在转移性去势抵抗性前列腺癌中的剂量学:治疗前影像与全身肿瘤剂量学及治疗结局的相关性

Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
PubMed 文献 · J Nucl Med · 2018-10-05

中位全身肿瘤吸收剂量为11.55 Gy,与12周PSA反应相关;达到PSA下降≥50%者的中位剂量为14.1 Gy,低于50%者为9.6 Gy(P<0.01)。筛选期68Ga-PSMA-11 PET/CT参数与肿瘤及正常组织剂量存在相关性。

要点

  • 中位全身肿瘤吸收剂量11.55 Gy与12周PSA反应相关。
  • PSA下降≥50%者中位剂量14.1 Gy,低于50%者9.6 Gy(P<0.01)。
  • 肿瘤剂量<10 Gy的11例中仅1例达到PSA下降≥50%。

核心结论

  • 177Lu-PSMA-617向肿瘤递送高吸收剂量,全身肿瘤剂量与PSA反应显著相关。
  • 接受低于10 Gy的患者不太可能达到PSA下降至少50%。
  • 筛选期68Ga-PET/CT参数与肿瘤和正常组织剂量显著相关,为患者特异性给药提供依据。

研究设计与样本

  • 筛选期行68Ga-PSMA-11 PET/CT,所有患者显示高PSMA表达。
  • 治疗后4、24、96小时行定量SPECT/CT,基于体素S值计算吸收剂量。

主要发现

  • 肾脏、颌下腺、腮腺、肝脏、脾脏和骨髓的平均吸收剂量分别为0.39、0.44、0.58、0.1、0.06和0.11 Gy/MBq。
  • 中位全身肿瘤吸收剂量为11.55 Gy,与12周PSA反应相关。
  • 达到PSA下降≥50%者的中位剂量为14.1 Gy,低于50%者为9.6 Gy(P<0.01)。
  • 肿瘤剂量<10 Gy的11例患者中仅1例达到PSA下降≥50%。
  • 筛选期PSMA PET全身肿瘤SUVmean与平均吸收剂量相关(r=0.62),腮腺SUVmax与吸收剂量相关(r=0.67)。

关键数值与推荐

  • PSA下降≥50%者中位肿瘤剂量14.1 Gy vs 下降<50%者9.6 Gy(P<0.01)。
  • 肿瘤剂量<10 Gy的11例中仅1例达到PSA下降≥50%。
  • 腮腺平均剂量随体重增加(r=-0.41)和体表面积增加(r=-0.37)而降低。

临床怎么用

  • 全身肿瘤吸收剂量与PSA反应相关,肿瘤剂量低于10 Gy者不太可能达到PSA下降至少50%。
  • 筛选期68Ga-PET/CT参数与肿瘤及正常组织剂量相关,可为患者特异性给药提供依据。
  • 肿瘤负荷较高的患者中观察到唾液腺和肾脏剂量降低。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-prostate-specific membrane antigen (PSMA)-617 enables targeted delivery of β-particle radiation to prostate cancer. We determined its radiation dosimetry and relationships to pretherapeutic imaging and outcomes. Methods: Thirty patients with prostate cancer receiving 177Lu-PSMA-617 within a prospective clinical trial (ACTRN12615000912583) were studied. Screening 68Ga-PSMA-11 PET/CT demonstrated high PSMA expression in all patients. After therapy, patients underwent quantitative SPECT/CT at 4, 24, and 96 h. Pharmacokinetic uptake and clearance at a voxel level were calculated and translated into absorbed dose using voxel S values. Volumes of interest were drawn on normal tissues and tumor to assess radiation dose, and a whole-body tumor dose was defined. Correlations between PSMA PET/CT parameters, dosimetry, and biochemical and therapeutic response were analyzed to identify relationships between absorbed dose, tumor burden, and patient physiology. Results: Mean absorbed dose to kidneys, submandibular and parotid glands, liver, spleen, and bone marrow was 0.39, 0.44, 0.58, 0.1, 0.06, and 0.11 Gy/MBq, respectively. Median whole-body tumor-absorbed dose was 11.55 Gy and correlated with prostate-specific antigen (PSA) response at 12 wk. A median dose of 14.1 Gy was observed in patients achieving a PSA decline of at least 50%, versus 9.6 Gy for those achieving a PSA decline of less than 50% (P < 0.01). Of 11 patients receiving a tumor dose of less than 10 Gy, only one achieved a PSA response of at least 50%. On screening PSMA PET, whole-body tumor SUVmean correlated with mean absorbed dose (r = 0.62), and SUVmax of the parotids correlated with absorbed dose (r = 0.67). There was an inverse correlation between tumor volume and mean dose to the parotids (r = -0.41) and kidneys (r = -0.43). The mean parotid dose was also reduced with increasing body mass (r = -0.41) and body surface area (r = -0.37). Conclusion:177Lu-PSMA-617 delivers high absorbed doses to tumor, with a significant correlation between whole-body tumor dose and PSA response. Patients receiving less than 10 Gy were unlikely to achieve a fall in PSA of at least 50%. Significant correlations between aspects of screening 68Ga-PET/CT and tumor and normal tissue dose were observed, providing a rationale for patient-specific dosing. Reduced salivary and kidney doses were observed in patients with a higher tumor burden. The parotid dose also reduced with increasing body mass and body surface area.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. J Nucl Med. 2018. PMID: 30291192. doi:10.2967/jnumed.118.219352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。